Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod and Pembrolizumab in Metastatic Melanoma
NCT03276832Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imiquimod and pembrolizumab in melanoma, sponsored by Mayo Clinic. Primary endpoints: Duration of Response at 16 months, Incidence of Adverse Events at 16 months and 3 more. Started Dec 2017; status: completed.
02
Drugs
imiquimodpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03276832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276832.